Anzeige
Mehr »
Donnerstag, 25.09.2025 - Börsentäglich über 12.000 News
Geheime Börsenchance: Ist das die bedeutendste Kupferentdeckung Kanadas?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DAFG | ISIN: CA01559R4008 | Ticker-Symbol: AGW0
Frankfurt
25.09.25 | 08:05
0,016 Euro
-46,67 % -0,014
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ALGERNON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ALGERNON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0290,05517:01

Aktuelle News zur ALGERNON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:06Algernon Pharmaceuticals Inc.: Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer's Detection95VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company...
► Artikel lesen
FrAlgernon Pharmaceuticals Inc (2): Algernon shareholders OK preferred share resolution1
FrAlgernon Pharmaceuticals Inc.: Algernon Announces Preferred Share Class Approved at Annual and Special Meeting1
04.09.Algernon Pharmaceuticals Inc (2): Algernon Pharma to change name to Algernon Health2
04.09.Algernon Pharmaceuticals Inc.: Algernon Pharmaceuticals Announces Name Change to Algernon Health109VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company...
► Artikel lesen
ALGERNON PHARMACEUTICALS Aktie jetzt für 0€ handeln
25.07.Algernon Pharmaceuticals Inc (2): Algernon Pharmaceuticals closes private placement3
24.07.Algernon Pharmaceuticals Inc.: Algernon Announces Closing of the Private Placement Financing3
01.07.Algernon Pharmaceuticals Inc (2): Algernon amends placement, closes $621k first tranche2
30.06.Algernon Pharmaceuticals Inc.: Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,0002
27.05.Algernon Pharmaceuticals Inc (2): Algernon arranges $1-million private placement2
23.05.Algernon closes NoBrainer acquisition2
23.05.Algernon Pharmaceuticals Inc.: Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition2
13.05.Algernon Pharmaceuticals Inc.: Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology212VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical...
► Artikel lesen
05.05.Algernon Pharmaceuticals Inc (2): Algernon Pharmaceuticals extends 4.75 million warrants3
05.05.Algernon Pharmaceuticals Inc.: Algernon Announces Warrant Extension1
08.04.Algernon Pharmaceuticals Inc (2): Algernon receives European patent allowance for NP-2511
08.04.Algernon Pharmaceuticals Inc.: Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease216VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical...
► Artikel lesen
06.03.Algernon Pharmaceuticals Inc.: Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing197VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
► Artikel lesen
05.02.Algernon Pharmaceuticals Inc.: Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity Investment198VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1